PEG-rHuMGDF stimulates platelet recovery after chemotherapy

Patients with lung cancer were treated with paclitaxel and carboplatin on day 1 and subsequently with either placebo (blue open circles, n = 12) or various doses of PEG-rHuMGDF (red closed circles, n = 38) and the platelet counts measured daily. The administration of PEG-rHuMGDF was associated with accelerated recovery of the platelet count. Twenty-one days after administration of the chemotherapy, 93 percent of the PEG-rHuMGDF-treated patients but none of those given placebo had recovered to their baseline platelet values (inset).